罗欣药业(002793) - 2023 Q3 - 季度财报

Revenue and Profitability - The company's revenue for Q3 2023 was ¥571,052,421.03, a decrease of 8.90% compared to ¥626,810,897.48 in the same period last year[3]. - The net profit attributable to shareholders for Q3 2023 was ¥102,625,370.88, representing a significant increase of 72.94% from ¥379,273,321.16 in the previous year[3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2023 was ¥103,870,920.92, a decrease of 72.83% from ¥382,367,280.09 in the previous year[3]. - The company's operating revenue for the first nine months of 2023 was ¥1,826,505,219.29, a decrease of 51.55% compared to the same period in 2022, primarily due to the inclusion of revenue from Shandong Luoxin Pharmaceutical (referred to as "Shangyao Luoxin") in the previous year[8]. - Total operating revenue for the current period is ¥1,826,505,219.29, a decrease of 51.6% from ¥3,769,618,686.08 in the previous period[18]. - Net profit for the current period is a loss of ¥286,580,699.37, compared to a loss of ¥483,606,451.16 in the previous period, indicating an improvement[19]. - The company reported a total comprehensive loss of ¥280,680,659.51 for the current period, compared to a loss of ¥449,801,750.82 in the previous period[19]. Cash Flow and Financial Position - The net cash flow from operating activities for the year-to-date period was ¥316,945,306.52, an increase of 127.82% compared to the same period last year[3]. - Cash flow from operating activities shows a net inflow of ¥316,945,306.52, a significant recovery from a net outflow of ¥1,139,298,807.70 in the previous period[20]. - The company reported a 751.06% increase in cash generated from investing activities, totaling ¥1,042,446,166.44, due to the recovery of financial support from Shangyao Luoxin[8]. - The company's cash and cash equivalents decreased from ¥1,433,805,083.16 to ¥963,865,685.47, a decline of approximately 32.7%[15]. - The total cash and cash equivalents at the end of Q3 2023 were 734,401,426.60 CNY, down from 764,728,288.27 CNY at the end of Q3 2022, reflecting a decrease of approximately 3.4% year-over-year[21]. - The cash outflow from financing activities totaled 2,864,568,444.80 CNY in Q3 2023, an increase of 18.3% from 2,422,084,076.19 CNY in Q3 2022[21]. Assets and Liabilities - Total assets as of the end of Q3 2023 were ¥5,858,998,970.23, a decrease of 27.83% from ¥8,107,824,389.64 at the end of the previous year[4]. - As of September 30, 2023, the total assets of Luoxin Pharmaceutical Group amounted to ¥5,858,998,970.23, a decrease from ¥8,117,960,973.82 at the beginning of the year, representing a decline of approximately 28.5%[15][16]. - The company's current assets decreased from ¥4,721,892,673.47 at the beginning of the year to ¥2,527,143,199.07, reflecting a reduction of about 46.5%[15]. - The total liabilities decreased from ¥4,811,482,861.20 to ¥2,800,540,680.28, indicating a decline of approximately 41.7%[16]. - The total equity attributable to shareholders decreased from ¥3,174,106,043.42 to ¥2,950,789,159.50, a decline of approximately 7.0%[16]. Borrowings and Financial Management - Long-term borrowings increased by 184.75% to ¥543,663,030.70, reflecting an optimization of the short-term and long-term borrowing structure[8]. - Short-term borrowings decreased by 62.73% to ¥886,436,756.95, as the company repaid loans and optimized its borrowing structure[8]. - The company received cash from borrowings amounting to 918,857,548.57 CNY in Q3 2023, a decrease of 54.7% compared to 2,028,066,391.28 CNY in Q3 2022[21]. - The company has fully repaid the financial assistance amounting to ¥1,061,244,755.50 provided to Modern Logistics and its subsidiaries, with no overdue repayments reported[13]. Research and Development - Research and development expenses decreased by 46.92% to ¥91,165,860.48, as most of the consistency evaluations for generic drugs were completed in the previous year[8]. - Research and development expenses decreased to ¥91,165,860.48, down 46.9% from ¥171,754,256.61 in the previous period[18]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 24,854, with the largest shareholder, Shandong Luoxin Holdings Co., Ltd., holding 21.79% of the shares[10]. Accounting and Audit - The company has made adjustments to its accounting policies due to the implementation of the new accounting standards effective January 1, 2023[4]. - Deferred tax assets were adjusted to 427,679,212.11 CNY as of January 1, 2023, reflecting an increase of 10,136,584.18 CNY due to the implementation of new accounting standards[22]. - The company did not conduct an audit for the Q3 2023 report, indicating that the financial results are unaudited[23].